Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Karthik Govindappa"'
Autor:
Mimieveshiofuo Ayala, Dominic P. Williams, Jeffrey Atkinson, Annie Delaunois, Yulia Tingle, Adedamola Olayanju, Ken Meecham, Sabine Pestel, Björn Lemmer, Swaminathan Sethu, Ana Alfirevic, James E. Sidaway, Christopher E. Goldring, Ailsa Dermody, Awel W. Williams, Junnat M. Hamdam, Trevor R.F. Smith, Kevin Park, Emma Smith, Mohammad Alhaidari, Rowena Sison-Young, Karthik Govindappa, Gerry Kenna, Jean-Pierre Valentin, Helen Box, Michael J. Cross, Rosalind E. Jenkins, Andreas Rothfuss, Jean-Michel Guillon, Richard Stebbings
Publikováno v:
Toxicology and Applied Pharmacology. 273:229-241
Safety pharmacology (SP) is an essential part of the drug development process that aims to identify and predict adverse effects prior to clinical trials. SP studies are described in the International Conference on Harmonisation (ICH) S7A and S7B guid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45178ceb5a609742f9897151e0020ac2
https://doi.org/10.1016/j.taap.2013.04.039
https://doi.org/10.1016/j.taap.2013.04.039
Autor:
Ian Kimber, Paul Quinn, Jean G. Sathish, Dean J. Naisbitt, Swaminathan Sethu, Richard Stebbings, Kevin Park, Munir Pirmohamed, Mike Boggild, Karthik Govindappa, Meenu Wadhwa
Publikováno v:
Clinical Immunology (Orlando, Fla.)
A subset of patients with relapsing-remitting multiple sclerosis (RRMS) on therapy with interferon beta (IFNβ) develop neutralising anti-drug antibodies (ADA) resulting in reduced, or loss of, therapeutic efficacy. The aims were to characterise the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8708719628b1ef7fae68a36ec882a9eb
https://doi.org/10.1016/j.clim.2013.05.008
https://doi.org/10.1016/j.clim.2013.05.008
Autor:
Jan Willem van der Laan, Ian Kimber, Dean J. Naisbitt, Meena Subramanyam, Swaminathan Sethu, Marque Todd, Karthik Govindappa, Jennifer Sims, David Jones, Richard J. Weaver, Stephen T. Holgate, B. Kevin Park, Neil French, Lolke de Haan, Jean G. Sathish, Christopher E.M. Griffiths, James D. Green, Marie Christine Bielsky, Gabriele Reichmann, Jonathan G. Moggs, Munir Pirmohamed
Publikováno v:
Nature Reviews. Drug Discovery
Key Points Immunomodulatory biologics are a class of biotechnology-derived therapeutic products that are designed to engage immune-relevant targets and are indicated in the treatment and management of a range of diseases, including immune-mediated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e40b3b36710a96b017a86f60343fd9c
http://europepmc.org/articles/PMC7097261
http://europepmc.org/articles/PMC7097261
Publikováno v:
European journal of clinical pharmacology. 71(11)
Interferon beta (IFN-β) is the drug of choice for treatment of relapsing forms of multiple sclerosis and is known to reduce the frequency and severity of relapses. This systematic review determines the occurrence of neutralising antibodies (NAbs) ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aa58cfa0e43f1194212bf655ac0222a
https://pubmed.ncbi.nlm.nih.gov/26268445
https://pubmed.ncbi.nlm.nih.gov/26268445
Autor:
Swaminathan Sethu, Karthik Govindappa, Kevin Park, Jean G. Sathish, Mohammad Alhaidari, Munir Pirmohamed
Publikováno v:
Archivum immunologiae et therapiae experimentalis. 60(5)
Currently, there is a significant rise in the development and clinical use of a unique class of pharmaceuticals termed as Biopharmaceuticals or Biologics, in the management of a range of disease conditions with, remarkable therapeutic benefits. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a10ead374fefbc330f6aaccc1a170de
https://pubmed.ncbi.nlm.nih.gov/22930363
https://pubmed.ncbi.nlm.nih.gov/22930363
Publikováno v:
European Journal of Clinical Pharmacology; Nov2015, Vol. 71 Issue 11, p1287-1298, 12p, 7 Charts
Autor:
Sethu, Swaminathan, Govindappa, Karthik, Alhaidari, Mohammad, Pirmohamed, Munir, Park, Kevin, Sathish, Jean
Publikováno v:
Archivum Immunologiae & Therapiae Experimentalis; Oct2012, Vol. 60 Issue 5, p331-344, 14p